<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623974</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0562</org_study_id>
    <nct_id>NCT00623974</nct_id>
  </id_info>
  <brief_title>Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia</brief_title>
  <official_title>A Phase II Study of Short-Term Use of Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      -To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared&#xD;
      to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive&#xD;
      neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck,&#xD;
      mediastinal lymph node neck dissections), with which serum calcium will be raised to&#xD;
      corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end&#xD;
      of the treatment course.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Teriparatide is designed to act like a natural human hormone called parathyroid hormone,&#xD;
      which can increase the blood levels of calcium. Calcium plus calcitriol is considered the&#xD;
      standard treatment for low calcium in the blood.&#xD;
&#xD;
      After scheduled surgery, the level of calcium in the blood will be monitored according to the&#xD;
      standard of care. Between 18 and 24 hours after the surgery, if calcium level drops below an&#xD;
      acceptable level, or participants develop symptoms of low calcium, they will be randomly&#xD;
      assigned (as in the toss of a coin) to 1 of 4 groups. One group (the &quot;standard-of-care&quot;&#xD;
      group) will receive calcium plus calcitriol alone, for 7 days. The other groups (the&#xD;
      &quot;teriparatide&quot; groups) will receive 1 of 3 different dose levels of teriparatide for 7 days,&#xD;
      plus calcium and calcitriol for 7 days. There is an equal chance of getting assigned to any&#xD;
      of these 4 groups, for the first 40 participants enrolled on this study. If enrolled after&#xD;
      that point, participants will have a greater chance of being assigned to the group showing&#xD;
      the best results.&#xD;
&#xD;
      Standard-of-Care Group:&#xD;
&#xD;
      If assigned to the standard-of-care group, participant will receive calcium and calcitriol&#xD;
      according to the standard schedule and dose. The calcium will either be given through a vein&#xD;
      or by mouth, and calcitriol will be given by mouth.&#xD;
&#xD;
      Teriparatide Group:&#xD;
&#xD;
      If assigned to a teriparatide group, participant will receive teriparatide by an injection&#xD;
      under the skin, twice a day for 7 days. They will be taught how to perform the injections&#xD;
      themselves, with a pen-sized device. While in the hospital, the hospital staff will watch&#xD;
      them perform the injections and offer help, if needed. If discharged from the hospital and&#xD;
      sent home before the 7 days of therapy are complete, they will continue giving themselves the&#xD;
      injections (through Day 7) at home. The pen should not be removed from refrigeration for more&#xD;
      than 2 -4 hours. Depending on what dose level of teriparatide assigned to receive, they may&#xD;
      have to give themselves up to 3 injections each time. In addition to teriparatide, they will&#xD;
      receive calcium and calcitriol, according to the standard schedule and dose. The calcium will&#xD;
      either be given through a vein or by mouth, and calcitriol by mouth.&#xD;
&#xD;
      Both Groups:&#xD;
&#xD;
      If blood calcium level has not returned to normal after the 7 days of treatment, participants&#xD;
      may need to continue receiving calcium and/or calcitriol for as long as the doctor decides it&#xD;
      is necessary.&#xD;
&#xD;
      They will be asked to keep a medication log (diary) of when they take the teriparatide and/or&#xD;
      calcium/calcitriol. The log should be returned to the research nurse on Day 8.&#xD;
&#xD;
      On Days 1-7, blood will be drawn to check the level of calcium twice a day (while in the&#xD;
      hospital) or once a day (while treated as an outpatient). These blood draws (about 1 teaspoon&#xD;
      each time) will be performed 2 hours before receiving teriparatide and/or calcium/calcitriol.&#xD;
&#xD;
      Blood will also be drawn to check calcium and parathyroid hormone levels after the study&#xD;
      treatment is over. The first of these blood draws (about 1 tablespoon each time) will be&#xD;
      performed at 3 days after receiving last dose of teriparatide and/or last dose of&#xD;
      calcium/calcitriol. The second blood draw will be performed at 4 weeks after the surgery.&#xD;
&#xD;
      Starting on Day 7, and again at 4 weeks after surgery, they will be asked to collect urine&#xD;
      over the course of a 24-hour period so calcium levels can be measured.&#xD;
&#xD;
      From Day 1 to Day 7, if discharged from the hospital and sent home, the study personnel will&#xD;
      call on the phone once a day to see how participants are doing. At 3 days after receiving the&#xD;
      last dose of teriparatide and/or the last dose of calcium/calcitriol, and at 4 weeks after&#xD;
      the surgery, they will be called again.&#xD;
&#xD;
      After the urine collection, blood draw, and phone call at 4 weeks after the surgery,&#xD;
      participation in the study is over.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to slow accrual.&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Success</measure>
    <time_frame>2 - 7 days post-treatment</time_frame>
    <description>A patient &quot;success&quot; is defined as a normal calcium level (Ca&gt;=8 and Ca&lt;= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hypocalcemia</condition>
  <arm_group>
    <arm_group_label>Calcium + Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide 40 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide 60 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide (Forteo)</intervention_name>
    <description>Subcutaneous Injection Every 12 Hours for 7 Days</description>
    <arm_group_label>Teriparatide 20 mcg</arm_group_label>
    <arm_group_label>Teriparatide 40 mcg</arm_group_label>
    <arm_group_label>Teriparatide 60 mcg</arm_group_label>
    <other_name>Forteo</other_name>
    <other_name>PTH</other_name>
    <other_name>Parathyroid Hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>1000 milligrams by mouth (PO) Every 12 Hours</description>
    <arm_group_label>Calcium + Calcitriol</arm_group_label>
    <arm_group_label>Teriparatide 20 mcg</arm_group_label>
    <arm_group_label>Teriparatide 40 mcg</arm_group_label>
    <arm_group_label>Teriparatide 60 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>0.25 micrograms PO Every 12 Hours</description>
    <arm_group_label>Calcium + Calcitriol</arm_group_label>
    <arm_group_label>Teriparatide 20 mcg</arm_group_label>
    <arm_group_label>Teriparatide 40 mcg</arm_group_label>
    <arm_group_label>Teriparatide 60 mcg</arm_group_label>
    <other_name>Rocaltrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are scheduled for total thyroidectomy, and/or extensive neck dissections&#xD;
             (pharyngectomy, laryngectomy, unilateral/bilateral/central neck, and/or mediastinal&#xD;
             lymph node neck dissections).&#xD;
&#xD;
          2. Patients who develop, between 18-24 hours after surgery, hypocalcemia as defined by a&#xD;
             corrected serum calcium &lt;8.0mg/dL. [Corrected serum calcium (mg/dL) = Measured calcium&#xD;
             + (4-albumin) x 0.8]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have jejunal tubes&#xD;
&#xD;
          2. Patients &lt;18 years old.&#xD;
&#xD;
          3. Treatment with teriparatide or calcitriol (Rocaltrol) within 1 month prior to surgery&#xD;
&#xD;
          4. Treatment with a bisphosphonate within 3 months prior to surgery&#xD;
&#xD;
          5. Hypercalcemia (corrected serum calcium &gt;10.5mg/dL) or hypocalcemia (corrected serum&#xD;
             calcium &lt;8.4mg/dL) on preoperative labs (drawn within 21 days of surgery)&#xD;
&#xD;
          6. Paget's disease of bone&#xD;
&#xD;
          7. Elevated alkaline phosphatase &gt; institutional upper limit of normal (ULN)&#xD;
&#xD;
          8. History of external beam irradiation to the skeleton&#xD;
&#xD;
          9. History of skeletal metastases&#xD;
&#xD;
         10. History of untreated gout&#xD;
&#xD;
         11. History of unstable angina pectoris&#xD;
&#xD;
         12. History of symptomatic orthostatic hypotension&#xD;
&#xD;
         13. Pregnancy (as screened by a serum/urine pregnancy test) or breast-feeding. Female&#xD;
             subjects of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             of surgery. Postmenopausal women (absence of menses for 12 months) or women with&#xD;
             history of hysterectomy or bilateral oophorectomy will not be required to have a&#xD;
             pregnancy test. Male and female patients of reproductive potential must agree to&#xD;
             utilize an effective form of contraception throughout the study period. The definition&#xD;
             of effective contraception will be based on the judgment of the Investigator or&#xD;
             designated associate.&#xD;
&#xD;
         14. Hepatic and renal dysfunction defined by the following parameters: (a) Serum AST&#xD;
             (SGOT) and ALT (SGPT) &gt; 3 times the institutional ULN, (b) Total serum bilirubin &gt; 2&#xD;
             times the institutional ULN, (c) Serum creatinine &gt; 1.5mg/dL or estimated creatinine&#xD;
             clearance &lt; 40mL/min&#xD;
&#xD;
         15. Psychiatric illness or social situation that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
         16. Concomitant use of digoxin&#xD;
&#xD;
         17. Patients may not be receiving any other investigational agents or have participated in&#xD;
             any investigational drug study within 28 days preceding the start of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mimi Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <results_first_submitted>August 13, 2010</results_first_submitted>
  <results_first_submitted_qc>August 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2010</results_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypocalcemia</keyword>
  <keyword>Teriparatide</keyword>
  <keyword>Forteo</keyword>
  <keyword>Calcium</keyword>
  <keyword>Calcitriol</keyword>
  <keyword>Rocaltrol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypocalcemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 2, 2008 to April 13, 2009. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>A total of 7 patients were consented and screened. None of the patients met study entry criteria and thus were not randomized to treatment. Due to slow accrual, the study was closed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Calcium + Calcitriol</title>
          <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="P2">
          <title>Teriparatide 20 Mcg</title>
          <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="P3">
          <title>Teriparatide 40 Mcg</title>
          <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="P4">
          <title>Teriparatide 60 Mcg</title>
          <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcium + Calcitriol</title>
          <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="B2">
          <title>Teriparatide 20 Mcg</title>
          <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="B3">
          <title>Teriparatide 40 Mcg</title>
          <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="B4">
          <title>Teriparatide 60 Mcg</title>
          <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
            </class>
            <class>
              <title>Male</title>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Success</title>
        <description>A patient &quot;success&quot; is defined as a normal calcium level (Ca&gt;=8 and Ca&lt;= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation.</description>
        <time_frame>2 - 7 days post-treatment</time_frame>
        <population>Terminated due low accrual, none of 7 participants met eligibility criteria therefore not treated nor randomized to study arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcium + Calcitriol</title>
            <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Teriparatide 20 Mcg</title>
            <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide 40 Mcg</title>
            <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
          </group>
          <group group_id="O4">
            <title>Teriparatide 60 Mcg</title>
            <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Success</title>
          <description>A patient &quot;success&quot; is defined as a normal calcium level (Ca&gt;=8 and Ca&lt;= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation.</description>
          <population>Terminated due low accrual, none of 7 participants met eligibility criteria therefore not treated nor randomized to study arms.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period 1 Year</time_frame>
      <desc>As no patient received study treatment, neither adverse events nor serious adverse events have occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>Calcium + Calcitriol</title>
          <description>1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="E2">
          <title>Teriparatide 20 Mcg</title>
          <description>Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="E3">
          <title>Teriparatide 40 Mcg</title>
          <description>Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
        <group group_id="E4">
          <title>Teriparatide 60 Mcg</title>
          <description>Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mimi Hu, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

